FDA Advisers Back Pfizer’s Paxlovid, Urge Info About Drug Interactions

A panel of FDA advisers on Thursday (March 16) agreed by a vote of 16-1 that Pfizer’s COVID-19 antiviral Paxlovid demonstrated a positive benefit-risk profile for treatment of mild-to-moderate coronavirus in certain adults, but with many committee members emphasizing that if the drug is approved, there should be clear information about drug-drug interactions on the product label. Advisers also raised concerns that physicians don’t understand when it’s appropriate to prescribe Paxlovid, and that people are being dissuaded from getting the...